Skip to main content Skip to section navigation Skip to footer
Sutro Logo high res
  • Who We Are
    • About Sutro
    • Leadership
      • Leadership Team
      • Board of Directors
      • Scientific Advisory Board
      • Clinical Advisory Board
    • Collaborations
  • Proprietary Platform
  • Pipeline
    • Overview
    • Scientific Publications
  • Investors
    • Overview
    • Press Releases
    • Events & Presentations
    • Financials
    • Stock Data
    • Governance
    • IR Resources
  • Careers
    • The Way We Work
    • DEIB
    • Sustainability
    • Internships
    • Philanthropy
      • Employee Engagement
  • Contact Us

Press Releases

Investors

Investors

  • Overview
  • Press Releases
  • Events & Presentations
  • Financials
    • Financial Results
    • SEC Filings
    • Annual Reports
  • Stock Data
    • Quote & Chart
    • Historical Data
    • Analyst Coverage
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • IR Resources
    • FAQ
    • Email Alerts
    • Contact
Aug 13, 2024 4:30 pm EDT
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
Jul 9, 2024 8:00 am EDT
Sutro Biopharma Appoints Dr. Barbara Leyman as Chief Business Development Officer
May 13, 2024 4:30 pm EDT
Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
Apr 30, 2024 8:00 am EDT
Sutro Biopharma Announces Initiation of Randomized Portion (Part 2) of REFRαME-O1 Trial
Apr 2, 2024 6:18 am EDT
Sutro Biopharma Announces Pricing of $75 Million Underwritten Offering
Apr 2, 2024 1:00 am EDT
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
Mar 25, 2024 4:30 pm EDT
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
Feb 6, 2024 4:05 pm EST
Sutro Biopharma to Participate in Upcoming Investor Conferences
Jan 4, 2024 4:05 pm EST
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
Dec 14, 2023 4:05 pm EST
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 23
  • Next Pagearrow_forward
rss_feed News RSS
  • emailEmail Alerts
  • contact_pageContacts
  • rss_feedRSS News Feed
Sutro Biopharma Corporate Site

Dedicated to patients
and changing the future of oncology

  • Follow
  • Follow
  • Follow
  • Follow

Follow us on social media

© 2025 Sutro Biopharma, Inc.
South San Francisco, California, U.S.A.

SITE MAP | PRIVACY POLICY | EMAIL ALERTS | CONTACT US | VISITOR GUIDE

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

Sutro Biopharma, Inc.
Powered by GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.